Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Medecine Sciences : M/S|April 7, 2006
[Regulation of energy metabolism by AMPK: a novel therapeutic approach for the treatment of metabolic and cardiovascular diseases]Marc Foretz, Nellie Taleux, Bruno Guigas, et al.
Critical Reviews in Biochemistry and Molecular Biology|June 5, 2010
AMPK inhibition in health and diseaseBenoit Viollet, Sandrine Horman, Jocelyne Leclerc, et al.
The Journal of Physiology|April 29, 2006
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disordersBenoit Viollet, Marc Foretz, Bruno Guigas, et al.
Surgery for Obesity and Related Diseases : Official Journal of the American Society for Bariatric Surgery|August 12, 2023
Perceptions of bariatric surgery in patients with type 2 diabetes: data from a self-administered questionnaireAlhassane Diallo, Fabrizio Andreelli, François Pattou, et al.
Therapie|April 10, 2021
Characteristics of insulinopenic and non insulinopenic diabetes related to immune checkpoint inhibitors: A French pharmacovigilance studyMarie Bastin, Marion Allouchery, Marion Sassier, et al.
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
Targeting the AMPK pathway for the treatment of Type 2 diabetesBenoit Viollet, Louise Lantier, Jocelyne Devin-Leclerc, et al.
Transplantation|June 30, 2004
Effect of venous drainage site on insulin action after simultaneous pancreas-kidney transplantationPalmina Petruzzo, Martine Laville, Lionel Badet, et al.
The Journal of Clinical Investigation|June 26, 2010
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy stateMarc Foretz, Sophie Hébrard, Jocelyne Leclerc, et al.
Diabetes|April 28, 2005
Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liverMarc Foretz, Nicolas Ancellin, Fabrizio Andreelli, et al.
Diabetes|March 29, 2006
5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocationBruno Guigas, Luc Bertrand, Nellie Taleux, et al.
Pageof 6